Ontology highlight
ABSTRACT:
SUBMITTER: Turner B
PROVIDER: S-EPMC6469695 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature
Turner Benjamin B Cree Bruce A C BAC Kappos Ludwig L Montalban Xavier X Papeix Caroline C Wolinsky Jerry S JS Buffels Regine R Fiore Damian D Garren Hideki H Han Jian J Hauser Stephen L SL
Journal of neurology 20190228 5
<h4>Objective</h4>The efficacy and safety of ocrelizumab, versus interferon (IFN) β-1a, for the treatment of relapsing multiple sclerosis (RMS) from the identically designed OPERA I (NCT01247324) and OPERA II (NCT01412333) phase III studies has been reported; here we present subgroup analyses of efficacy endpoints from the pooled OPERA I and OPERA II populations.<h4>Methods</h4>Patients with RMS were randomized to either ocrelizumab 600 mg administered by intravenous infusion every 24 weeks or s ...[more]